Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
NEW YORK, Feb. 15, 2018 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Philip Morris International Inc. ("Philip Morris") (NYSE:PM) securities between July 26, 2016 and December 20, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sb/philip-morris-international-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) there were irregularities in the clinical experiments that underpin Philip Morris' application to the FDA for approval of its iQOS smoking device; and (2) consequently, defendants' statements about Philip Morris' business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Philip Morris you have until February 20, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sb/philip-morris-international-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
